Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;18(11):1106-1125.
doi: 10.2174/1570159X18666200528142429.

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease

Sahil Khan  1 , Kalyani H Barve  1 , Maushmi S Kumar  1
Affiliations
Review

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease

Sahil Khan et al. Curr Neuropharmacol. 2020.

Abstract

Background: The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other form of dementia. However, due to the non-feasibility of such methods, to diagnose and conclude the conditions, medical practitioners use tests that examine a patient's mental ability.

Objective: Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The cause for most Alzheimer's cases still remains unknown except where genetic distinctions have been observed. Thus, a standard drug regimen ensues in every Alzheimer's patient, irrespective of the cause, which may not always be beneficial in halting or reversing the disease progression. To provide a better life to such patients by suppressing existing symptoms, early diagnosis, curative therapy, site-specific delivery of drugs, and application of hyphenated methods like artificial intelligence need to be brought into the main field of Alzheimer's therapeutics.

Methods: In this review, we have compiled existing hypotheses to explain the cause of the disease, and highlighted gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics and quantum dots as advancements in the existing strategies to manage Alzheimer's.

Conclusion: Biomarkers, brain-imaging, and theranostics, along with artificial intelligence, are understood to be the future of the management of Alzheimer's.

Keywords: Artificial intelligence; biomarkers; brain imaging; gene therapy; mild cognitive impairment; theranostics.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Mechanisms involved in pathogenesis of Alzheimer’s disease. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (2)
Fig. (2)
Current strategies in treatment and newer strategies in early detection and treatment of Alzheimer’s disease. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
See this image and copyright information in PMC

References

    1. Duthey B. https://www.who.int/medicines/areas/priority_medicines/BP6_11Alzheimer.p...
    1. Barage S.H., Sonawane K.D. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides. 2015;52:1–18. doi: 10.1016/j.npep.2015.06.008. - DOI - PubMed
    1. Grimm M.O.W., Hartmann T. Recent understanding of the molecular mechanisms of Alzheimer’s disease. J. Addict. Res. Ther. 2012;004(S5)
    1. Begcevic I., Brinc D., Brown M., Martinez-Morillo E., Goldhardt O., Grimmer T., Magdolen V., Batruch I., Diamandis E.P. Brain-related proteins as potential CSF biomarkers of Alzheimer’s disease: A targeted mass spectrometry approach. J. Proteomics. 2018;182:12–20. doi: 10.1016/j.jprot.2018.04.027. - DOI - PubMed
    1. Mullane K., Williams M. Alzheimer’s disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochem. Pharmacol. 2018;158:359–375. doi: 10.1016/j.bcp.2018.09.026. - DOI - PubMed